A Study of HS-10587 in Patients With Advanced Solid Tumors

Summary

This is a Phase I, multicenter, open-label clinical trial with dose escalation/dose expansion phases, designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) profiles, and antitumor efficacy characteristics of HS-10587 in patients with MTAP-deleted advanced solid tumors.

Timeline

Start

2026-06-04

Primary completion

2027-12-31

Completion

2028-06-30

Drugs

Indications